A clinical experience of single agent bevacizumab in relapsing ovarian cancer

Gynecologic Oncology

Volumn 129, Issue 3, 2013, Pages 459-462

  Emile, George ^a   Chauvenet, Laure ^a   Tigaud, Jean Marie ^a   Chidiac, Jean ^a   Pujade Lauraine, Eric ^a   Alexandre, Jerome ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bevacizumab; Hypertension; Intestinal perforation; Ovarian cancer; Relapse

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BLOOD PRESSURE MONITORING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTRITIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PULMONARY HYPERTENSION; RECTUM HEMORRHAGE; RECURRENT CANCER; TREATMENT RESPONSE; VAGINA BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84877581486     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.02.035     Document Type: Article

References (28)

1. WHO, IARC GLOBOCAN Cancer Incidence and Mortality Worldwide in 2008 2008
2. R. Ozols, B. Bundy, and B. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
3. R.A. Burger, M.F. Brady, and M.A. Bookman Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2783
4. T. Perren, A.C. Swart, and J. Pfisterer A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
5. J. Folkman, E. Merler, and C. Abernathy Isolation of a tumor factor responsible for angiogenesis J Exp Med 133 1971 275 288
6. J. Folkman What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 1990 4 6
7. D. Hanahan, and R.A. Weinberg Cell 144 2011 646 674
8. J. Yoneda, H. Kuniyasu, M.A. Crispens, J.E. Price, C.D. Bucana, and I.J. Fidler Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice J Natl Cancer Inst 90 1998 447 454
9. L.G. Presta, H. Chen, and S.J. O'Connor Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599
10. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
11. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
12. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
13. R.A. Burger, M.W. Sill, and B.J. Monk Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
14. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5518
15. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
16. I. Vergote, G.J. Rustin, and E.A. Eisenhauer Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer] Gynecologic Cancer Intergroup J Natl Cancer Inst 92 2000 1534 1535
17. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
18. E. Pujade-Lauraine, and J. Alexandre Update of randomized trials in recurrent disease Ann Oncol 22 Suppl. 8 2011 viii61 viii64
19. A.N. Gordon, J.T. Fleagle, and D. Guthrie Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
20. G. Ferrandina, M. Ludovisi, and D. Lorusso Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer J Clin Oncol 26 2008 890 896
21. A. Lortholary, R. Largillier, and B. Weber Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) Ann Oncol 23 2012 346 352
22. E. Pujade-Lauraine, F. Hilpert, and B. Weber AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 30 2012 LBA5002 (Suppl.; abstr)
23. M. Markman The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy Ann Oncol 22 Suppl. 8 2011 viii69 viii71
24. J.D. Wright, A.A. Secord, and T.M. Numnum A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer Int J Gynecol Cancer 18 2008 400 406
25. O. Mir, R. Coriat, and L. Cabanes An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity Oncologist 16 2011 1325 1332
26. A. De Stefano, C. Carlomagno, and S. Pepe Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients Cancer Chemother Pharmacol 68 2011 1207 1213
27. J.P. Diaz, W.P. Tew, and O. Zivanovic Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma Gynecol Oncol 116 2010 335 339
28. K. Pietzner, R. Richter, and R. Chekerov Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group Anticancer Res (Greece) 31 2011 2679 2682